Granules India rises on getting USFDA`s nod for Metoprolol Succinate ER Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Granules India is currently trading at Rs. 324.25, up by 3.80 points or 1.19% from its previous closing of Rs. 320.45 on the BSE.
The scrip opened at Rs. 321.75 and has touched a high and low of Rs. 324.75 and Rs. 320.05 respectively. So far 43273 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 267.85 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 330.95 and Rs. 313.75 respectively. The current market cap of the company is Rs. 7856.71 crore.
The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.03% and 29.95% respectively.
Granules India has received US Food & Drug Administration (USFDA) approval for the ANDA filed for Metoprolol Succinate ER Tablets 25/50/100/200 mg. It is therapeutically equivalent to the reference listed drug, Toprol-XL Extended-Release Tablets, 25 mg, 50 mg, 100 mg and 200 mg, of Sequel Therapeutics, LLC.
The Company had filed two ANDAs for the same product with different technologies. This is the second ANDA approval for Metoprolol Succinate ER tablets that is therapeutically equivalent to the RLD, Toprol- XL, ER tablets for Granules.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
